NBTX VS ATXS Stock Comparison

Performance

NBTX
51/100

NBTX returned -7.36% in the last 12 months. Based on the other stocks in its sector with an average return of -7.41%, its performance is above average giving it a grade of 50 of 100.

ATXS
10/100

ATXS returned -47.56% in the last 12 months. Based on SPY's performance of -13.91%, its performance is below average giving it a score of 10 of 100.

Sentiment

NBTX
63/100

NBTX had a bullish sentiment score of 63.40% across Twitter and StockTwits over the last 12 months. It had an average of 30.90 posts, 5.83 comments, and 30.90 likes per day.

ATXS

"Sentiment" not found for ATXS

Volatility

NBTX
20/100

NBTX has had a lower than average amount of volatility over the last 12 months giving it a grade of 20 of 100.

ATXS
42/100

ATXS has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

Technicals

NBTX

"Technicals" not found for NBTX

ATXS
11/100

ATXS receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

NBTX

"Earnings" not found for NBTX

ATXS
10/100

ATXS has missed earnings 9 times in the last 20 quarters.

Profit

NBTX

"Profit" not found for NBTX

ATXS
10/100

Out of the last 20 quarters, ATXS has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Nanobiotix S.A. American Depositary Shares Summary

Nasdaq / NBTX

Healthcare

Biotechnology

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Astria Therapeutics, Inc. Common Stock Summary

Nasdaq / ATXS

Healthcare

Biotechnology

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Power up your portfolio